CLINICAL_TRIALS
trial_result
· 2015-09-28
Clinical Trial Update: Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer [Phase 2]
Summary
A Phase 2 clinical trial evaluating lapatinib in patients with relapsed or refractory inflammatory breast cancer has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 2 | Status: COMPLETED